Form 13-F position report

ELEVATION ONCOLOGY INC

Reported by GEODE CAPITAL MANAGEMENT LLC

ELEV CUSIP 28623U101 Manager CIK 0001214717

Reported 1,031,576 shares, up 683,143 (196.1%) from the prior quarter.

Reported value 55.8%; share count 196.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 1,031,576 Quarter-end amount reported
Reported value $2,785,502 Fair value at quarter end
Consecutive quarters held 12 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 94000
2021-12-31 126000
2022-03-31 66000
2022-06-30 36000
2022-09-30 102000
2022-12-31 85000
2023-03-31 247722
2023-06-30 206970
2023-09-30 152547
2023-12-31 123626
2024-03-31 1787915
2024-06-30 2785502
2024-09-30 666038
2024-12-31 651364
2025-03-31 307428
2025-06-30 197802
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for ELEVATION ONCOLOGY INC held by GEODE CAPITAL MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -538,656 (-100.0%) 0 $0 2025-11-12
Q2 2025 Reduced 538,656 -647,663 (-54.6%) < 0.01% $197,802 2025-08-08
Q1 2025 Added 1,186,319 +28,747 (2.5%) < 0.01% $307,428 2025-05-13
Q4 2024 Added 1,157,572 +47,487 (4.3%) < 0.01% $651,364 2025-02-12
Q3 2024 Added 1,110,085 +78,509 (7.6%) < 0.01% $666,038 2024-11-12
Q2 2024 Added 1,031,576 +683,143 (196.1%) < 0.01% $2,785,502 2024-08-09
Q1 2024 Added 348,433 +118,297 (51.4%) < 0.01% $1,787,915 2024-05-13
Q4 2023 Unchanged 230,136 0 (0.0%) < 0.01% $123,626 2024-02-13
Q3 2023 Added 230,136 +93,971 (69.0%) < 0.01% $152,547 2023-11-13
Q2 2023 Added 136,165 +5,785 (4.4%) < 0.01% $206,970 2023-08-11
Q1 2023 Added 130,380 +40,037 (44.3%) < 0.01% $247,722 2023-05-15
Q4 2022 Reduced 90,343 -284 (-0.3%) < 0.01% $85,000 2023-02-13
Q3 2022 Added 90,627 +64,361 (245.0%) < 0.01% $102,000 2022-11-14
Q2 2022 Unchanged 26,266 0 (0.0%) < 0.01% $36,000 2022-08-12
Q1 2022 Added 26,266 +5,245 (25.0%) < 0.01% $66,000 2022-05-13
Q4 2021 Added 21,021 +8,865 (72.9%) < 0.01% $126,000 2022-02-11
Q3 2021 New 12,156 +12,156 (0.0%) < 0.01% $94,000 2021-11-12

Who else reported the position

94 managers reported ELEVATION ONCOLOGY INC for Q2 2024.

Managers reporting ELEVATION ONCOLOGY INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Logos Global Management LP Added 3,850,000 +2,850,000 0.84% $10,395,000 2 qtrs
FARALLON CAPITAL MANAGEMENT LLC Reduced 3,598,418 -288,245 0.04% $9,715,729 2 qtrs
TANG CAPITAL MANAGEMENT LLC Unchanged 3,060,000 0 0.84% $8,262,000 7 qtrs
Frazier Life Sciences Management L P New 2,958,579 +2,958,579 0.37% $7,988,163 1 qtr
Aisling Capital Management LP Unchanged 2,834,910 0 3.31% $7,654,257 13 qtrs
BlackRock Inc Added 2,490,249 +2,318,348 < 0.01% $6,723,672 12 qtrs
Balyasny Asset Management LLC Reduced 2,483,645 -571,834 0.01% $6,705,842 2 qtrs
BRAIDWELL LP Added 2,477,614 +99,967 0.21% $6,689,558 2 qtrs
venBio Partners LLC Reduced 2,434,255 -261,878 2.84% $6,572,489 13 qtrs
Hudson Bay Capital Management LP Added 2,397,768 +886,867 0.03% $6,473,974 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 09, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,031,576
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.